Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment

摘要: Metastatic malignant melanoma is a frequently fatal cancer. In recent years substantial therapeutic progress has occurred with the development of targeted kinase inhibitors and immunotherapeutics. Targeted therapies often result in rapid clinical benefit however responses are seldom durable. Immune can durable disease control but may not be immediate. Optimal cancer therapy requires both this likely best achieved by combining To achieve this, detailed understanding immune consequences various inhibitors, development, trial currently used to treat required.